CMRX - Chimerix, Inc.
1.7300 0.00 (0.00%)
After hours: 4:06PM EST
| Previous Close | 1.7200 |
| Open | 1.7100 |
| Bid | 1.7000 x 3100 |
| Ask | 1.7700 x 1200 |
| Day's Range | 1.6700 - 1.7650 |
| 52 Week Range | 1.2500 - 4.4000 |
| Volume | 349,200 |
| Avg. Volume | 476,755 |
| Market Cap | 106.191M |
| Beta (5Y Monthly) | 1.58 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.3480 |
| Earnings Date | Feb 24, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.00 |
- GlobeNewswire
Chimerix to Report Fourth Quarter and Year End 2019 Financial Results and Provide an Operational Update on February 25, 2020
Chimerix (CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Tuesday, February 25, 2020 at 8:30 a.m. ET to report financial results for the fourth quarter and full-year ended December 31, 2019, and to provide a business overview. An archived webcast will be available on the Chimerix website approximately two hours after the event. Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases.
- Simply Wall St.
Investors Who Bought Chimerix (NASDAQ:CMRX) Shares Five Years Ago Are Now Down 96%
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to see...
- GuruFocus.com
Steven Cohen Renews His Interest in Verastem
Guru invests in restructuring cancer drug developer Continue reading...
- GlobeNewswire
Chimerix Presents Data Supporting Brincidofovir as a Potential Treatment for Smallpox at 2020 American Society for Microbiology Biothreats Meeting
Chimerix (CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announces that data in support of brincidofovir (BCV) as a potential treatment for smallpox were highlighted in an oral presentation and poster at the 2020 American Society for Microbiology (ASM) Biothreats Meeting taking place January 28-30, 2020 in Arlington, Virginia. Chimerix is developing BCV as a medical countermeasure against smallpox.
- Zacks
Has Chimerix (CMRX) Outpaced Other Medical Stocks This Year?
Is (CMRX) Outperforming Other Medical Stocks This Year?
- Simply Wall St.
Here's Why We're Watching Chimerix's (NASDAQ:CMRX) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- Insider Monkey
Is Chimerix Inc (CMRX) A Good Stock To Buy?
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]
- GlobeNewswire
Chimerix Presents Updated Results from Phase 2 Clinical Trial of DSTAT in Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia at American Society of Hematology Annual Meeting
Chimerix, Inc. (CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that data relating to its dociparstat sodium (DSTAT) program, formerly known as CX-01, were presented at the 61st American Society of Hematology Annual Meeting, in Orlando, FL. The poster, titled “Updated Study Results for CX-01, an Inhibitor of CXCL12/CXCR4, With Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS,” was presented by Eric Huselton, M.D., Assistant Professor of Medicine at the University of Rochester on December 9, 2019. As reported in the published study abstract, 20 patients with refractory myelodysplastic syndrome (MDS) (n = 9) or refractory acute myeloid leukemia (AML) (n = 11) were enrolled of which 15 were considered evaluable for response with a bone marrow biopsy after cycle 2.
- Thomson Reuters StreetEvents
Edited Transcript of CMRX earnings conference call or presentation 5-Nov-19 1:30pm GMT
Q3 2019 Chimerix Inc Earnings Call and Operational Updates
- Simply Wall St.
Should You Be Concerned About Chimerix, Inc.'s (NASDAQ:CMRX) Historical Volatility?
If you're interested in Chimerix, Inc. (NASDAQ:CMRX), then you might want to consider its beta (a measure of share...
- GlobeNewswire
Chimerix Announces Third Quarter 2019 Financial Results and Provides Operational Update
– Final Data from Phase 2 Randomized Trial of DSTAT in First-line AML Support Enhanced Durability of Response, Event-free Survival and Overall Survival Benefit – – End of Phase.
- GlobeNewswire
Chimerix to Present at Upcoming Investor Conferences
DURHAM, N.C., Nov. 04, 2019 -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious.
- GlobeNewswire
Chimerix to Announce Third Quarter 2019 Financial Results and Provide an Operational Update on November 5, 2019
Chimerix, Inc. (CMRX), a biopharmaceutical company focused on accelerating the development of innovative medicines to treat patients with cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Tuesday, November 5, 2019 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2019, and to provide an operational update. A live audio webcast of the call will also be available on the Investors’ section of the Company's website, www.chimerix.com. Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases.
- Simply Wall St.
Have Insiders Been Buying Chimerix, Inc. (NASDAQ:CMRX) Shares?
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
- Benzinga
The Daily Biotech Pulse: Safety Scare For Anaptys' Psoriasis Drug, NewLink Genetics To Merge With Lumos, Insider Buy Props Up VBI Vaccines
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 30.) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ...
- GlobeNewswire
Chimerix Announces Exclusive Global License Agreement with SymBio Pharmaceuticals for Brincidofovir
Chimerix (CMRX), a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases, today announces an exclusive global license agreement with SymBio Pharmaceuticals, Ltd (SymBio), under which SymBio has exclusively licensed the worldwide rights to develop, manufacture and commercialize brincidofovir in all human indications, excluding the prevention and treatment of smallpox. Moving forward, SymBio will be responsible for all future development and commercialization as well as manufacturing costs associated with brincidofovir in the licensed indications.
- GlobeNewswire
Chimerix to Present at 2019 Cantor Global Healthcare Conference
DURHAM, N.C., Sept. 27, 2019 -- Chimerix (NASDAQ:CMRX) today announced that Mike Sherman, Chief Executive Officer, will present a corporate overview at the upcoming 2019 Cantor.
- Simply Wall St.
Those Who Purchased Chimerix (NASDAQ:CMRX) Shares Five Years Ago Have A 91% Loss To Show For It
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We don't wish...
- Zacks
Chimerix (CMRX) Reports Q2 Loss, Lags Revenue Estimates
Chimerix (CMRX) delivered earnings and revenue surprises of -105.88% and -37.48%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Chimerix Announces Second Quarter 2019 Financial Results and Operational Update
Pipeline Transformed with Acquisition of Global Rights to Late Stage Oncology Asset (CX-01) with Fast Track and Orphan Drug Designation Phase 3 Trial of CX-01 in Front-Line.
- Zacks
Chimerix (CMRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Chimerix (CMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Chimerix Announces Exclusive Worldwide License of Phase 3 Ready CX-01 for Development in Acute Myeloid Leukemia
Chimerix (CMRX), today announced the completion of an exclusive worldwide license of CX-01 from Cantex Pharmaceuticals, Inc. Chimerix intends to move quickly into Phase 3 development of CX-01 for the treatment of Acute Myeloid Leukemia (AML) in the first-line setting. “We are pleased to have made such rapid progress in repositioning the company and transforming our pipeline with this important cancer therapy.
